Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
COVID-19
SARS-CoV-2
antibody response
neutralizing antibodies
sterilizing immunity
vaccine
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
28
02
2022
received:
02
02
2022
accepted:
07
03
2022
pubmed:
1
4
2022
medline:
10
8
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global COVID-19 pandemic. One possibility to control the pandemic is to induce sterilizing immunity through the induction and maintenance of neutralizing antibodies preventing SARS-CoV-2 from entering human cells to replicate in. We report the construction and in vitro and in vivo characterization of a SARS-CoV-2 subunit vaccine (PreS-RBD) based on a structurally folded recombinant fusion protein consisting of two SARS-CoV-2 Spike protein receptor-binding domains (RBD) fused to the N- and C-terminus of hepatitis B virus (HBV) surface antigen PreS to enable the two unrelated proteins serving as immunologic carriers for each other. PreS-RBD, but not RBD alone, induced a robust and uniform RBD-specific IgG response in rabbits. Currently available genetic SARS-CoV-2 vaccines induce mainly transient IgG The PreS-RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity against SARS-CoV-2 and HBV by stopping viral replication through the inhibition of cellular virus entry.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global COVID-19 pandemic. One possibility to control the pandemic is to induce sterilizing immunity through the induction and maintenance of neutralizing antibodies preventing SARS-CoV-2 from entering human cells to replicate in.
METHODS
We report the construction and in vitro and in vivo characterization of a SARS-CoV-2 subunit vaccine (PreS-RBD) based on a structurally folded recombinant fusion protein consisting of two SARS-CoV-2 Spike protein receptor-binding domains (RBD) fused to the N- and C-terminus of hepatitis B virus (HBV) surface antigen PreS to enable the two unrelated proteins serving as immunologic carriers for each other.
RESULTS
PreS-RBD, but not RBD alone, induced a robust and uniform RBD-specific IgG response in rabbits. Currently available genetic SARS-CoV-2 vaccines induce mainly transient IgG
CONCLUSION
The PreS-RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity against SARS-CoV-2 and HBV by stopping viral replication through the inhibition of cellular virus entry.
Identifiants
pubmed: 35357709
doi: 10.1111/all.15305
pmc: PMC9111473
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2431-2445Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
N Engl J Med. 2021 Oct 28;385(18):1680-1689
pubmed: 34379914
N Engl J Med. 1999 Aug 12;341(7):468-75
pubmed: 10441602
J Exp Med. 1970 Aug 1;132(2):283-99
pubmed: 4101345
J Allergy Clin Immunol. 2019 Mar;143(3):1067-1076
pubmed: 30445057
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826
pubmed: 34915551
J Allergy Clin Immunol. 2005 Aug;116(2):347-54
pubmed: 16083789
NPJ Vaccines. 2021 Aug 16;6(1):104
pubmed: 34400651
Nat Rev Immunol. 2006 Oct;6(10):761-71
pubmed: 16998509
J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5
pubmed: 21281875
Sci Rep. 2020 Dec 11;10(1):21779
pubmed: 33311634
Allergy. 2021 Mar;76(3):878-883
pubmed: 32734595
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498
pubmed: 29221580
EBioMedicine. 2020 Sep;59:102953
pubmed: 32855110
Nat Med. 2021 Dec;27(12):2144-2153
pubmed: 34697502
J Clin Med. 2021 Dec 15;10(24):
pubmed: 34945172
J Med Virol. 2022 Apr;94(4):1728-1733
pubmed: 34897752
Allergy. 2021 Jan;76(1):131-149
pubmed: 32249442
Allergy. 2022 Jun;77(6):1885-1894
pubmed: 34652831
J Hepatol. 2011 Jul;55(1):29-37
pubmed: 21145866
Allergy. 2022 May;77(5):1616-1620
pubmed: 35188670
Allergy. 2021 Jun;76(6):1617-1618
pubmed: 33320974
Emerg Infect Dis. 2022 Feb;28(2):460-462
pubmed: 34860154
EBioMedicine. 2016 Sep;11:58-67
pubmed: 27568223
Science. 2007 Sep 14;317(5844):1554-7
pubmed: 17872445
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Allergy. 2021 Jun;76(6):1922-1924
pubmed: 33340417
Immunol Lett. 2017 Sep;189:19-26
pubmed: 28472641
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
Allergy. 2022 Jun;77(6):1658-1660
pubmed: 34816455
EBioMedicine. 2019 Dec;50:421-432
pubmed: 31786130
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
J Allergy Clin Immunol. 2018 Aug;142(2):497-509.e9
pubmed: 29361332
J Immunol Methods. 2011 Feb 28;365(1-2):67-75
pubmed: 21182843
Allergy. 2022 Aug;77(8):2431-2445
pubmed: 35357709
EBioMedicine. 2016 Sep;11:5-6
pubmed: 27485030
Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):99-103
pubmed: 34849667
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
J Immunol. 2009 May 15;182(10):6298-306
pubmed: 19414783
J Allergy Clin Immunol. 2011 Jun;127(6):1562-70.e6
pubmed: 21411130
Allergy. 2021 Dec;76(12):3627-3641
pubmed: 33999439
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
EBioMedicine. 2016 Sep;11:43-57
pubmed: 27650868
Allergy. 2022 Jan;77(1):230-242
pubmed: 34453317
Virol J. 2013 Jul 20;10:239
pubmed: 23870415
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
JAMA Cardiol. 2021 Dec 1;6(12):1446-1450
pubmed: 34374740